---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-24-000096"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:15:55.480023+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ARC-9 interim analysis: EZFB combo improves PFS (HR 0.27) and OS (HR 0.37) vs regorafenib in 3L mCRC

## Summary
- Cohort B (n=112) met primary endpoint: PFS HR 0.27 (p<0.0001), median 6.2 vs 2.1 months.
- OS key secondary: HR 0.37 (p=0.0003), median OS 19.7 vs 9.5 months favoring EZFB.
- ORR 17.3% for EZFB vs 2.7% for regorafenib; safety profile consistent with FOLFOX/bev.
- Data selected for oral presentation at 2024 ASCO Annual Meeting on June 2, 2024.

## SEC filing metadata
- accession: 0001724521-24-000096
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000096/0001724521-24-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000096/rcus-20240523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-24-000096
- JSON: https://secwatch.observer/filing/0001724521-24-000096.json
- Plain text: https://secwatch.observer/filing/0001724521-24-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.